The treatment paradigm for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is undergoing a significant transformation, driven by recent regulatory approvals and ongoing clinical investigations into novel immunotherapies. The U.S. Food and Drug Administration’s (FDA) approval of MSD’s Keytruda (pembrolizumab) in June 2025 for resectable LA HNSCC patients with a PD-L1 Combined Positive Score (CPS) of 1 or higher, based on data from the KEYNOTE-689 trial, marks a pivotal moment. This approval enables the use of Keytruda as neoadjuvant monotherapy followed by adjuvant treatment in combination with radiotherapy, with or without cisplatin, and subsequently as a single agent. Concurrently, the GORTEC-sponsored NIVOPOSTOP trial has presented compelling results for adjuvant Opdivo (nivolumab), although regulatory submission by Bristol Myers Squibb (BMS) is yet to be confirmed. These advancements are particularly impactful given the considerable patient population affected by LA HNSCC, with over 63,000 diagnoses recorded in 2024 across the United States, France, Germany, Italy, Spain, and the United Kingdom. Despite these strides, significant unmet needs persist, offering a compelling opportunity for further therapeutic development.
Key Treatment Pathways and Unmet Needs in LA HNSCC
The Non-Surgical Cohort: A Significant Untapped Market
A substantial portion of LA HNSCC patients, approximately 40% according to GlobalData’s high-prescriber survey, currently receive definitive chemoradiotherapy without undergoing surgical intervention. This approach is frequently favored by clinicians, particularly for laryngeal, oropharyngeal, and hypopharyngeal cancers, where organ preservation is a primary objective. Oral cavity tumors, in contrast, are predominantly managed through surgical resection. This large patient segment, which does not currently fall within the scope of existing immunooncology (IO) approaches like KEYNOTE-689 and NIVOPOSTOP – both designed with a surgical pathway in mind – represents a critical target for future therapeutic development aimed at reducing recurrence rates and improving long-term outcomes. The focus on organ preservation underscores a patient-centric approach to care, aiming to minimize the functional and aesthetic impact of treatment.
An Aging Population and Performance Status Considerations
Another significant demographic within the LA HNSCC patient population comprises older adults and individuals with poor performance status. GlobalData’s "Head and Neck Squamous Cell Carcinoma: Eight-Market Drug Forecast and Market Analysis 2024–2034" report projects that patients aged 65 and older, who currently constitute approximately 39% of HNSCC patients, will represent 44% of this population by 2034. This demographic shift highlights the growing importance of age-appropriate treatment strategies. However, subgroup analyses from the KEYNOTE-689 trial indicated a potentially attenuated benefit of pembrolizumab in patients over 65 years of age. Furthermore, individuals with poor performance status remain significantly underrepresented in clinical trials, making it challenging to ascertain the efficacy and safety of novel therapies in this vulnerable group. Addressing these specific patient needs is crucial for advancing equitable and effective cancer care.
Subgroup Analysis and Emerging Evidence Gaps
The KEYNOTE-689 trial, while groundbreaking, enrolled a relatively limited number of patients with specific tumor subtypes, including hypopharyngeal cancers and certain p16-negative and p16-positive oropharyngeal disease. Notably, the trial did not demonstrate a significant benefit in the hypopharyngeal subgroup, where the event-free survival (EFS) hazard ratio (HR) was recorded at 2.28 (95% confidence interval [CI]: 0.79, 6.56). This finding suggests that current IO therapies may not be universally effective across all LA HNSCC subtypes. Furthermore, current National Comprehensive Cancer Network (NCCN) guidelines do not recommend pembrolizumab for human papillomavirus (HPV)-positive oropharyngeal disease. Insights from a key opinion leader interviewed by GlobalData suggest that pembrolizumab will likely be prescribed to approximately 30% of all LA HNSCC patients, with the strongest evidence base currently supporting its use in oral cavity tumors. This underscores the need for further research to define the precise role of pembrolizumab in different HNSCC molecular subtypes and anatomical locations.
The PD-L1 Negative Patient Population and Nivolumab’s Potential
Patients with a PD-L1 CPS score below 1 were largely excluded from the KEYNOTE-689 trial and are therefore ineligible for pembrolizumab treatment. However, this patient group represented approximately 14% of the NIVOPOSTOP trial population. Should Opdivo receive regulatory approval, these patients would remain eligible for treatment with nivolumab, presenting a potential therapeutic option for a segment currently underserved by pembrolizumab. This highlights the importance of diverse trial inclusion criteria to ensure that novel therapies address the broadest possible patient population.
Urgent Surgical Intervention: A Subset Requiring Distinct Approaches
A smaller, yet critically important, segment of LA HNSCC patients presents with borderline resectable or highly symptomatic tumors that necessitate immediate surgical intervention. These individuals may not be suitable candidates for neoadjuvant therapeutic strategies. The KEYNOTE-689 trial observed delays in surgical procedures in 12% of patients in the neoadjuvant IO arm, compared to 3.3% in the standard-of-care arm. This finding suggests that while neoadjuvant therapies can be beneficial, careful consideration of the potential for treatment delays is warranted, particularly in patients requiring prompt surgical management. Stage IVb patients were also excluded from the KEYNOTE-689 trial, indicating a need for evidence generation in more advanced disease stages.
Future Directions and Combination Strategies
Harnessing the Synergistic Potential of Combination Therapies
The distinct mechanisms of action of Keytruda and Opdivo present an intriguing opportunity for combination therapy. Keytruda has demonstrated efficacy in reducing the risk of distant recurrence, while Opdivo has shown promise in improving locoregional control. Given that locoregional progression remains a primary driver of morbidity and mortality in HNSCC, even in the presence of distant metastases, a local therapeutic agent incorporated into a perioperative pembrolizumab backbone could specifically address residual locoregional risk that current IO monotherapies may not fully mitigate. Furthermore, novel agents could complement existing IO therapies as part of cisplatin-sparing treatment strategies, potentially reducing the toxicity associated with traditional chemoradiotherapy regimens.
A Timeline of Progress and Future Outlook
The journey of immunotherapies in LA HNSCC has been marked by a series of significant milestones:
- Pre-2025: Head and neck cancers were largely treated with surgery, radiotherapy, and chemotherapy, with limited options for immunotherapy in the perioperative setting. Clinical trials exploring IO agents were ongoing, laying the groundwork for future approvals.
- June 2025: The FDA approves MSD’s Keytruda (pembrolizumab) for resectable LA HNSCC patients with PD-L1 CPS ≥ 1, based on KEYNOTE-689 data, enabling neoadjuvant and adjuvant use. This marks a paradigm shift, introducing immunotherapy into the perioperative management of this disease.
- Ongoing (Post-June 2025): The GORTEC-sponsored NIVOPOSTOP trial reports meaningful results for adjuvant Opdivo (nivolumab). BMS’s decision regarding regulatory submission remains a key point of interest for the oncology community.
- Present and Near Future: Focus shifts to understanding the optimal role of Keytruda across different LA HNSCC subtypes, exploring its efficacy in patient groups excluded from KEYNOTE-689 (e.g., older patients, those with poor performance status, hypopharyngeal tumors), and investigating combination strategies to address remaining unmet needs, particularly locoregional control. The development of novel agents that can complement IO therapies, potentially in cisplatin-sparing regimens, is also a significant area of research.
Implications for Patient Care and Pharmaceutical Development
The recent advancements in LA HNSCC treatment, particularly the approval of Keytruda and the promising data from Opdivo trials, represent substantial progress. They validate the perioperative approach for the first time in this disease, offering new hope to patients. However, the substantial proportion of patients who fall outside the current IO treatment pathways, including those managed non-surgically, older patients, and those with specific tumor characteristics, signifies a wide-open landscape for further therapeutic innovation. Pharmaceutical companies are likely to focus on developing agents that can address these specific unmet needs, either as monotherapies or in combination with existing IO agents. This includes exploring novel targets, refining treatment selection criteria based on biomarkers, and conducting trials in underrepresented patient populations. The evolving understanding of HNSCC biology and the growing success of immunotherapies suggest a future where personalized and more effective treatment strategies become the norm for this challenging disease. The ongoing research and development in this field are critical for improving survival rates, reducing treatment-related toxicities, and enhancing the quality of life for patients battling LA HNSCC.
Leave a Reply